INVESTIGADORES
MARELLI Belkis Ester
artículos
Título:
Oral immunization with live Lactococcus lactis expressing rotavirus VP8* subunit
Autor/es:
MARELLI, B; PEREZ, A.R.; BANCHIO, C.; DE MENDOZA, D.; MAGNI, C.
Revista:
JOURNAL OF VIROLOGICAL METHODS
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Año: 2011 vol. 175 p. 28 - 37
ISSN:
0166-0934
Resumen:
Rotaviruses are the major cause of worldwide infectious diarrhea in children and vaccination is considered
to be the most effective way to control these infections. The development of a mucosal live vaccine
using the food-grade lactic acid bacteria Lactococcus lactis as antigen vehicle is an attractive and safe
vaccination strategy against rotavirus. In this study, the construction of recombinant L. lactis strains able
to produce the rotavirus spike-protein subunit VP8* in cytoplasmic, secreted and cell wall-anchored
forms is reported. Evaluation of the immune response generated after immunization was conducted in a
mouse model. The present study shows that animals inoculated orally with the L. lactis strain producing
the cytoplasmic form of VP8* (LL1) developed significant levels of intestinal IgA antibodies while animals
receiving L. lactis producing the cell wall-anchored VP8* form (LL3) exhibited anti-VP8* antibodies at both
intestinal and systemic levels. Furthermore, it was observed that intestinal antibodies of the LL1-treated
group and serum antibodies of the LL3-treated group were able to block rotavirus infection by 50% and
100%, respectively. These encouraging results represent a step towards the development of a new and
safe mucosal vaccine against rotavirus.Lactococcus lactis as antigen vehicle is an attractive and safe
vaccination strategy against rotavirus. In this study, the construction of recombinant L. lactis strains able
to produce the rotavirus spike-protein subunit VP8* in cytoplasmic, secreted and cell wall-anchored
forms is reported. Evaluation of the immune response generated after immunization was conducted in a
mouse model. The present study shows that animals inoculated orally with the L. lactis strain producing
the cytoplasmic form of VP8* (LL1) developed significant levels of intestinal IgA antibodies while animals
receiving L. lactis producing the cell wall-anchored VP8* form (LL3) exhibited anti-VP8* antibodies at both
intestinal and systemic levels. Furthermore, it was observed that intestinal antibodies of the LL1-treated
group and serum antibodies of the LL3-treated group were able to block rotavirus infection by 50% and
100%, respectively. These encouraging results represent a step towards the development of a new and
safe mucosal vaccine against rotavirus.L. lactis strains able
to produce the rotavirus spike-protein subunit VP8* in cytoplasmic, secreted and cell wall-anchored
forms is reported. Evaluation of the immune response generated after immunization was conducted in a
mouse model. The present study shows that animals inoculated orally with the L. lactis strain producing
the cytoplasmic form of VP8* (LL1) developed significant levels of intestinal IgA antibodies while animals
receiving L. lactis producing the cell wall-anchored VP8* form (LL3) exhibited anti-VP8* antibodies at both
intestinal and systemic levels. Furthermore, it was observed that intestinal antibodies of the LL1-treated
group and serum antibodies of the LL3-treated group were able to block rotavirus infection by 50% and
100%, respectively. These encouraging results represent a step towards the development of a new and
safe mucosal vaccine against rotavirus.L. lactis strain producing
the cytoplasmic form of VP8* (LL1) developed significant levels of intestinal IgA antibodies while animals
receiving L. lactis producing the cell wall-anchored VP8* form (LL3) exhibited anti-VP8* antibodies at both
intestinal and systemic levels. Furthermore, it was observed that intestinal antibodies of the LL1-treated
group and serum antibodies of the LL3-treated group were able to block rotavirus infection by 50% and
100%, respectively. These encouraging results represent a step towards the development of a new and
safe mucosal vaccine against rotavirus.L. lactis producing the cell wall-anchored VP8* form (LL3) exhibited anti-VP8* antibodies at both
intestinal and systemic levels. Furthermore, it was observed that intestinal antibodies of the LL1-treated
group and serum antibodies of the LL3-treated group were able to block rotavirus infection by 50% and
100%, respectively. These encouraging results represent a step towards the development of a new and
safe mucosal vaccine against rotavirus.